Strides Pharma Science Ltd

Strides Pharma Science Ltd

₹ 360 0.00%
02 Jun - close price
About

Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products.[1] The company's pharmaceutical products are sold in over 100 countries.[2]
The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure.[3]

Key Points

Business Verticals
Regulated Markets
This business vertical comprises businesses in the US and Other Regulated Markets, including the UK, the EU, Canada, Australia, and South Africa.

  • Market Cap 3,246 Cr.
  • Current Price 360
  • High / Low 392 / 268
  • Stock P/E
  • Book Value 245
  • Dividend Yield 0.00 %
  • ROCE -0.15 %
  • ROE -8.93 %
  • Face Value 10.0

Pros

Cons

  • Company has low interest coverage ratio.
  • Promoter holding has decreased over last quarter: -2.61%
  • The company has delivered a poor sales growth of 5.33% over past five years.
  • Promoter holding is low: 28.3%
  • Company has a low return on equity of -2.97% over last 3 years.
  • Contingent liabilities of Rs.1,175 Cr.
  • Promoters have pledged 81.8% of their holding.
  • Earnings include an other income of Rs.91.9 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
619 782 794 832 908 688 721 794 866 940 897 865 986
598 648 662 698 772 758 759 817 868 936 844 892 871
Operating Profit 20 134 132 134 137 -70 -37 -23 -1 4 53 -27 115
OPM % 3% 17% 17% 16% 15% -10% -5% -3% -0% 0% 6% -3% 12%
-152 57 41 -1 12 -78 -38 -5 9 -52 57 68 20
Interest 40 37 37 35 42 41 44 42 49 55 68 58 81
Depreciation 45 49 53 53 52 55 57 61 61 60 62 60 61
Profit before tax -217 105 83 46 55 -244 -175 -131 -103 -163 -20 -78 -7
Tax % 5% 3% 7% 23% 21% 15% 4% 3% 128% 17% 197% -5% -106%
Net Profit -207 102 77 35 44 -209 -168 -127 29 -135 19 -82 -14
EPS in Rs -22.77 11.56 9.03 4.22 5.14 -22.87 -18.11 -13.55 3.25 -15.13 2.53 -8.86 -1.06
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Dec 2011 Dec 2012 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
2,550 962 1,341 1,196 2,861 2,755 2,845 2,178 2,752 3,316 3,070 3,688
2,111 861 1,567 967 2,486 2,228 2,448 1,982 2,351 2,779 3,201 3,544
Operating Profit 439 101 -226 229 374 527 398 197 401 537 -131 145
OPM % 17% 10% -17% 19% 13% 19% 14% 9% 15% 16% -4% 4%
133 959 3,281 874 63 291 643 303 -30 109 -112 92
Interest 195 79 109 47 168 183 196 79 156 150 177 261
Depreciation 104 31 56 64 131 126 154 117 174 206 233 243
Profit before tax 273 949 2,890 992 137 509 690 303 42 289 -653 -268
Tax % 14% 11% 39% 15% 31% 12% 1% -9% 27% 11% 27% 21%
Net Profit 234 847 1,767 844 95 446 684 330 31 258 -474 -212
EPS in Rs 38.44 143.92 296.43 141.78 12.15 44.71 74.25 36.25 4.06 29.93 -51.25 -22.44
Dividend Payout % 5% 1% 170% 76% 41% 10% 3% 8% 345% 8% -0% -7%
Compounded Sales Growth
10 Years: 14%
5 Years: 5%
3 Years: 10%
TTM: 20%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 13%
Stock Price CAGR
10 Years: -9%
5 Years: 0%
3 Years: -5%
1 Year: 11%
Return on Equity
10 Years: 18%
5 Years: 1%
3 Years: -3%
Last Year: -9%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Dec 2011 Dec 2012 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
58 59 60 60 89 89 90 90 90 90 90 90
Reserves 1,313 1,967 947 1,085 2,569 2,659 2,374 2,559 2,438 2,687 2,269 2,122
2,643 1,594 547 892 3,542 3,700 2,520 3,221 2,235 2,348 3,025 3,030
1,341 1,175 543 438 1,211 1,598 1,601 1,937 1,369 1,844 1,556 1,397
Total Liabilities 5,355 4,796 2,096 2,475 7,410 8,046 6,585 7,807 6,131 6,969 6,940 6,638
3,188 3,017 555 701 2,679 2,980 2,977 3,648 2,099 2,219 2,347 2,414
CWIP 285 241 99 171 815 780 620 453 413 447 291 48
Investments -0 0 443 630 1,341 1,525 588 702 549 697 540 490
1,882 1,538 999 972 2,576 2,762 2,400 3,005 3,070 3,605 3,762 3,687
Total Assets 5,355 4,796 2,096 2,475 7,410 8,046 6,585 7,807 6,131 6,969 6,940 6,638

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Dec 2011 Dec 2012 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
457 139 -272 83 73 288 187 60 205 481 -258 44
-659 771 4,044 50 -2,205 -1,222 570 -145 1,321 -522 -119 302
89 -990 -3,319 -421 2,944 338 -1,016 194 -1,709 -16 421 -214
Net Cash Flow -113 -80 454 -288 812 -596 -259 110 -184 -56 45 133

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Dec 2011 Dec 2012 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 77 183 99 119 132 132 113 165 124 122 144 129
Inventory Days 139 328 90 135 149 209 146 294 254 329 285 257
Days Payable 169 344 137 153 188 221 188 299 259 311 260 220
Cash Conversion Cycle 47 168 52 102 92 120 71 160 119 140 168 165
Working Capital Days -106 18 53 -29 96 63 117 155 95 116 210 150
ROCE % 11% 27% 116% 58% 8% 12% 16% 6% 5% 8% -5% -0%

Shareholding Pattern

Numbers in percentages

Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
29.71 29.69 29.69 29.67 29.62 29.60 29.60 30.60 30.37 31.08 30.90 28.28
26.78 26.96 25.16 24.82 25.80 24.96 19.85 19.66 21.21 21.43 18.98 18.85
19.40 15.28 16.65 16.08 14.62 20.44 21.08 18.82 16.63 15.07 18.44 17.88
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.40 0.40 0.40
24.11 28.07 28.50 29.42 29.96 25.00 29.47 30.92 31.79 32.05 31.29 34.60

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls